US FDA May Start Missing ANDA User Fee Goals – In Order To Speed Approvals
Executive Summary
Agency will work past generic goal dates if approval can be achieved quickly thereafter, but now must create policy defining criteria for those situations.
You may also be interested in...
Missed ANDA Nods Mostly Due To 'Imminent Approval'
US FDA will miss goal dates to reach speedier generic drug application approvals, but says decisions will be case by case.
ANDA User Fee Misses Are Mostly Part Of 'Imminent Approval' Process
US FDA will miss goal dates to reach speedier generic drug application approvals, but says decisions will be case by case.
ANDA Reviews Sometimes Miss GDUFA Goal Dates To Get Quicker Approval, But How Often?
Preliminary performance data suggests only a handful of applications receiving US FDA action by the end of FY 2018 actually missed their review goals.